ABSTRACT
INTRODUCTION: Bardet-Biedl Syndrome (BBS) is a rare, multisystemic ciliopathy with an incidence of obesity of 89%. Mutations in genes encoding BBS proteins are linked to reduced leptin sensitivity of hypothalamic POMC neurons and reduced activation of the melanocortin-4 receptor (MC4R) pathway due to deficient α-MSH production by hypothalamic POMC neurons. The MC4R pathway is involved in controlling body weight and energy metabolism, and its disruption is linked to hyperphagia and obesity. Setmelanotide is an MC4R agonist that counteracts deficiencies in the MC4R pathway of individuals with BBS. AREAS COVERED: Data from clinical trials were reviewed along with information available from setmelanotide's approval for treatment of obesity in people ages ≥6y with a clinical diagnosis of BBS. EXPERT OPINION: Setmelanotide is available as a daily injectable that can be used for amelioration of obesity in people with Bardet-Biedl syndrome. Its cost is substantial, which may limit its use, but among those who respond, setmelanotide can reduce body mass dramatically and potentially improve comorbid conditions associated with obesity. Setmelanotide treatment has generally tolerable side effects, primarily injection site reactions and nausea/vomiting that generally improve with continued use; almost all people using setmelanotide experience marked skin darkening due to off-target activation of cutaneous MC1R.
Subject(s)
Bardet-Biedl Syndrome , alpha-MSH , Humans , Adult , Child , alpha-MSH/therapeutic use , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/complications , Bardet-Biedl Syndrome/genetics , Pro-Opiomelanocortin/metabolism , Pro-Opiomelanocortin/therapeutic use , Obesity/complications , Obesity/drug therapyABSTRACT
INTRODUCTION: Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with hyperphagia, a pathologic insatiable hunger, due to impaired signaling in the melanocortin-4 receptor (MC4R) pathway. The impact of hyperphagia on the lives of patients with BBS and their families has not been fully characterized. METHODS: Patients with BBS or their caregivers who participated in clinical trials of the MC4R agonist setmelanotide (NCT03013543 and NCT03746522) were included in this qualitative study. Telephone interviews were conducted using a semistructured interview guide to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment. RESULTS: Nineteen interviews (8 patients, 11 caregivers) were conducted. The term "hunger" (rather than "hyperphagia") was used in interviews to ensure common terminology. Before setmelanotide treatment, all participants described their (or their child's) hunger as all-consuming, leading to an obsessive focus on food. Nine participants recalled intense, continuous hunger, and most participants (5 patients, 10 caregivers) reported lack of control with eating. Negative impacts on patients' lives included difficulties with concentration, emotional and physical manifestations, and impaired relationships. All participants experienced or observed improvements in hunger and health outcomes during treatment, the most meaningful of which included weight loss and decrease in obsessive focus on food and food-seeking behaviors. All participants reported improvements in either physical and/or emotional well-being and being satisfied with setmelanotide. CONCLUSIONS: Hyperphagia and resulting food-seeking behaviors have notable negative impacts on quality of life in patients with BBS and caregivers. Setmelanotide improved hyperphagia, reduced body weight and obsessive focus on food, and facilitated improvements in physical and emotional well-being for both patients and caregivers. TRIAL REGISTRATION: NCT03013543 and NCT03746522.
Subject(s)
Bardet-Biedl Syndrome , Quality of Life , Child , Humans , Caregivers/psychology , Bardet-Biedl Syndrome/drug therapy , alpha-MSH/therapeutic useABSTRACT
Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.
Subject(s)
Bardet-Biedl Syndrome , Diabetes Mellitus, Type 2 , Metabolic Syndrome , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/genetics , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide-1 Receptor , Humans , Weight LossABSTRACT
Primary cilia are microtubule-based organelles present on most cells that regulate many physiological processes, ranging from maintaining energy homeostasis to renal function. However, the role of these structures in the regulation of behavior remains unknown. To study the role of cilia in behavior, we employ mouse models of the human ciliopathy, Bardet-Biedl Syndrome (BBS). Here, we demonstrate that BBS mice have significant impairments in context fear conditioning, a form of associative learning. Moreover, we show that postnatal deletion of BBS gene function, as well as congenital deletion, specifically in the forebrain, impairs context fear conditioning. Analyses indicated that these behavioral impairments are not the result of impaired hippocampal long-term potentiation. However, our results indicate that these behavioral impairments are the result of impaired hippocampal neurogenesis. Two-week treatment with lithium chloride partially restores the proliferation of hippocampal neurons which leads to a rescue of context fear conditioning. Overall, our results identify a novel role of cilia genes in hippocampal neurogenesis and long-term context fear conditioning.
Subject(s)
Bardet-Biedl Syndrome/genetics , Fear/drug effects , Neurogenesis/drug effects , Neurons/metabolism , Animals , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/pathology , Cell Proliferation/drug effects , Cilia/genetics , Cilia/metabolism , Cilia/pathology , Disease Models, Animal , Fear/physiology , Hippocampus/metabolism , Hippocampus/pathology , Humans , Lithium/pharmacology , Memory Disorders/drug therapy , Memory Disorders/genetics , Memory Disorders/pathology , Mice , Microtubule-Associated Proteins/genetics , Neurogenesis/genetics , Neurons/pathologyABSTRACT
Bardet-Biedl syndrome (BBS) is a pleiotropic autosomal recessive ciliopathy affecting multiple organs. The development of potential disease-modifying therapy for BBS will require concurrent targeting of multi-systemic manifestations. Here, we show for the first time that monosialodihexosylganglioside accumulates in Bbs2-/- cilia, indicating impairment of glycosphingolipid (GSL) metabolism in BBS. Consequently, we tested whether BBS pathology in Bbs2-/- mice can be reversed by targeting the underlying ciliary defect via reduction of GSL metabolism. Inhibition of GSL synthesis with the glucosylceramide synthase inhibitor Genz-667161 decreases the obesity, liver disease, retinal degeneration and olfaction defect in Bbs2-/- mice. These effects are secondary to preservation of ciliary structure and signaling, and stimulation of cellular differentiation. In conclusion, reduction of GSL metabolism resolves the multi-organ pathology of Bbs2-/- mice by directly preserving ciliary structure and function towards a normal phenotype. Since this approach does not rely on the correction of the underlying genetic mutation, it might translate successfully as a treatment for other ciliopathies.
Subject(s)
Bardet-Biedl Syndrome/genetics , Cilia/genetics , Ciliopathies/genetics , Proteins/genetics , Animals , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/pathology , Cell Differentiation/drug effects , Cilia/pathology , Ciliopathies/drug therapy , Ciliopathies/pathology , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Gangliosides/biosynthesis , Gangliosides/genetics , Glucosyltransferases/antagonists & inhibitors , Glucosyltransferases/genetics , Glycosphingolipids/biosynthesis , Glycosphingolipids/genetics , Mice, KnockoutABSTRACT
AIM: To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet-Biedl syndrome (BBS). MATERIALS AND METHODS: Individuals aged 12 years and older with BBS received once-daily setmelanotide. The dose was titrated every 2 weeks to establish the individual therapeutic dose (≤3 mg); treatment continued for an additional 10 weeks. Participants who lost 5 kg or more (or ≥5% of body weight if <100 kg at baseline) continued into the 52-week extension phase. The primary outcome was mean percent change from baseline in body weight at 3 months. Hunger scores and safety were secondary outcomes. RESULTS: From February 2017 and February 2018, 10 individuals were screened; eight completed the 3-month treatment phase and seven completed the extension phase. Mean percent change in body weight from baseline to 3 months was -5.5% (90% CI, -9.3% to -1.6%; n = 8); change from baseline was -11.3% (90% CI, -15.5% to -7.0%; n = 8) at 6 months and -16.3% (90% CI, -19.9% to -12.8%; n = 7) at 12 months. All participants reported at least one treatment-emergent adverse event (AE), most commonly injection-site reaction. No AEs led to study withdrawal or death. Most, morning, and average hunger scores were reduced across time points. CONCLUSIONS: Setmelanotide reduced body weight and hunger in individuals with BBS and had a safety profile consistent with previous reports. Setmelanotide may be a treatment option in individuals with BBS-associated obesity and hyperphagia.
Subject(s)
Bardet-Biedl Syndrome , Receptor, Melanocortin, Type 4 , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/epidemiology , Humans , Obesity/complications , Obesity/drug therapy , alpha-MSH/analogs & derivatives , alpha-MSH/therapeutic useABSTRACT
The ciliopathies are a group of phenotypically overlapping disorders caused by structural or functional defects in the primary cilium. Although disruption of numerous signaling pathways and cellular trafficking events have been implicated in ciliary pathology, treatment options for affected individuals remain limited. Here, we performed a genome-wide RNAi (RNA interference) screen to identify genetic suppressors of BBS4, one of the genes mutated in Bardet-Biedl syndrome (BBS). We discovered 10 genes that, when silenced, ameliorate BBS4-dependent pathology. One of these encodes USP35, a negative regulator of the ubiquitin proteasome system, suggesting that inhibition of a deubiquitinase, and subsequent facilitation of the clearance of signaling components, might ameliorate BBS-relevant phenotypes. Testing of this hypothesis in transient and stable zebrafish genetic models showed this posit to be true; suppression or ablation of usp35 ameliorated hallmark ciliopathy defects including impaired convergent extension (CE), renal tubule convolution, and retinal degeneration with concomitant clearance of effectors such as ß-catenin and rhodopsin. Together, our findings reinforce a direct link between proteasome-dependent degradation and ciliopathies and suggest that augmentation of this system might offer a rational path to novel therapeutic modalities.
Subject(s)
Ciliopathies/genetics , Endopeptidases/genetics , Ubiquitin-Specific Proteases/genetics , Animals , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome/genetics , CRISPR-Cas Systems/genetics , Cell Line , Cilia/genetics , Genetic Techniques , Humans , Microtubule-Associated Proteins/genetics , Phenotype , Retinal Degeneration/genetics , Wnt Signaling Pathway/genetics , Zebrafish , Zebrafish Proteins/geneticsABSTRACT
A 28-year-old man diagnosed with diabetes mellitus and systemic hypertension presented with a medical history of sudden onset retrosternal discomfort followed by loss of consciousness and generalised tonic clonic seizures. Examination revealed obesity, polysyndactyly and retinal pigment dystrophy. He was diagnosed to have acute myocardial infarction and left posterior watershed infarct. He was also diagnosed to have Bardet-Biedl syndrome based on clinical features. He was managed symptomatically and is currently doing well on regular follow-up in the outpatient clinic.
Subject(s)
Anticoagulants/therapeutic use , Bardet-Biedl Syndrome/physiopathology , Magnetic Resonance Imaging , Myocardial Infarction/physiopathology , Obesity/complications , Adult , Bardet-Biedl Syndrome/complications , Bardet-Biedl Syndrome/diagnostic imaging , Bardet-Biedl Syndrome/drug therapy , Humans , Male , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/drug therapy , Myocardial Infarction/etiology , Neuroimaging , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Bardet-Biedl Syndrome/complications , Bardet-Biedl Syndrome/drug therapy , Bardet-Biedl Syndrome , Thromboembolism/complications , Thromboembolism , Acenocoumarol/therapeutic use , Dyspnea/complications , Pulmonary Artery/pathology , Pulmonary Artery , Bed RestABSTRACT
No disponible
Subject(s)
Humans , Female , Brachial Plexus , Nerve Block/methods , Nerve Block , Bardet-Biedl Syndrome/complications , Bardet-Biedl Syndrome/diagnosis , Anesthesia, Conduction/methods , Anesthesia, Conduction , Bardet-Biedl Syndrome/drug therapy , Anesthesia, Conduction/trendsABSTRACT
Ciliopathies, a class of rare genetic disorders, present often with retinal degeneration caused by protein transport defects between the inner segment and the outer segment of the photoreceptors. Bardet-Biedl syndrome is one such ciliopathy, genetically heterogeneous with 17 BBS genes identified to date, presenting early onset retinitis pigmentosa. By investigating BBS12-deprived retinal explants and the Bbs12(-/-) murine model, we show that the impaired intraciliary transport results in protein retention in the endoplasmic reticulum. The protein overload activates a proapoptotic unfolded protein response leading to a specific Caspase12-mediated death of the photoreceptors. Having identified a therapeutic window in the early postnatal retinal development and through optimized pharmacological modulation of the unfolded protein response, combining three specific compounds, namely valproic acid, guanabenz, and a specific Caspase12 inhibitor, achieved efficient photoreceptor protection, thereby maintaining light detection ability in vivo.
Subject(s)
Apoptosis/drug effects , Bardet-Biedl Syndrome/drug therapy , Photoreceptor Cells/drug effects , Retina/drug effects , Unfolded Protein Response/drug effects , Vision, Ocular/drug effects , Animals , Biological Transport , Caspase 12/metabolism , Caspase Inhibitors/pharmacology , Caspase Inhibitors/therapeutic use , Chaperonins/deficiency , Chaperonins/genetics , Cilia/metabolism , Cilia/pathology , Cytoprotection , Endoplasmic Reticulum Stress/drug effects , Guanabenz/pharmacology , Guanabenz/therapeutic use , Kinetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Phenotype , Photoreceptor Cells/enzymology , Photoreceptor Cells/pathology , Retina/metabolism , Retina/pathology , Signal Transduction , Tissue Culture Techniques , Valproic Acid/pharmacology , Valproic Acid/therapeutic useABSTRACT
PURPOSE: To evaluate and compare the protective effect of tauroursodeoxycholic acid (TUDCA) on photoreceptor degeneration in different models of retinal degeneration (RD) in mice. METHODS: Bbs(M390R/M390R) mice were injected subcutaneously twice a week, from P40 to P120, and rd10 mice were injected every 3 days from P6 to P38 with TUDCA or vehicle (0.15 M NaHCO(3)). Rd1 and rd16 mice were injected daily from P6 to P30 with TUDCA or vehicle. Retinal structure and function were determined at multiple time points by electroretinography (ERG), optical coherence tomography (OCT), and histology. RESULTS: The amplitude of ERG b-waves was significantly higher in TUDCA-treated Bbs1 and rd10 animals than in controls. Retinal thickness on OCT was slightly greater in treated Bbs1 animals than in the controls. Histologically, outer segments were preserved, and the outer nuclear layer was significantly thicker in the treated Bbs1 and rd10 mice than in the controls. Bbs1(M390R/M390R) mice developed less obesity than the control Bbs1(M390R/M390R) while receiving TUDCA. The Rd1 and rd16 mice showed no improvement with TUDCA treatment, and the rd1 mice did not have normal weight gain during treatment. CONCLUSIONS: TUDCA treatment preserved ERG b-waves and the outer nuclear layer in Bbs1(M390R/M390R) mice, and prevented obesity assessed at P120. TUDCA treatment preserved ERG b-waves and the outer nuclear layer in the rd10 mice to P30. TUDCA is a prime candidate for treatment of humans with retinal degeneration, especially those with Bardet-Biedl syndrome, whom it may help not only with the vision loss, but with the debilitating obesity as well.
Subject(s)
Bardet-Biedl Syndrome/drug therapy , Cholagogues and Choleretics/therapeutic use , Disease Models, Animal , Obesity/prevention & control , Retinitis Pigmentosa/drug therapy , Taurochenodeoxycholic Acid/therapeutic use , Animals , Bardet-Biedl Syndrome/genetics , Cholagogues and Choleretics/administration & dosage , Electroretinography/drug effects , Injections, Subcutaneous , Mice , Microtubule-Associated Proteins/genetics , Retina/physiopathology , Retinal Degeneration/drug therapy , Retinal Degeneration/physiopathology , Retinitis Pigmentosa/physiopathology , Taurochenodeoxycholic Acid/administration & dosage , Tomography, Optical CoherenceABSTRACT
The ciliopathies are a class of rare human genetic disease whose aetioligies lie in defective primary cilia. Typical ciliopathies include Bardet-Biedl syndrome (BBS), nephronophthisis (NPHP), Jeune, Joubert, oro-facial-digital (OFD1) and Meckel (MKS) syndromes. All ciliopathies have the common denominator of renal disease, often including tubular cysts. In this study, we have modelled a range of ciliopathies in zebrafish and shown in all cases that knocking down these genes causes cystic lesions in the kidney. We have identified two drugs, rapamycin and roscovitine, which ameliorate the renal phenotype, both morphologically and functionally. This is the first study in which zebrafish has been used to identify potential therapeutic modalities for ciliopathic renal disease, and the results pave the way for further investigations in mammalian models.